| CAS号 | 107724-20-9 |
| 中文别名 | 伊普利酮 |
| 英文别名 | (7A,11A,17A)-9,11-EPOXY-17-HYDROXY-3-OXO-PREGN-4-ENE-7,21-DICARBOXYLIC ACID G-LACTONE METHYL ESTER; pregn-4-ene-7,21-dicarboxylic acid 9,11-epoxy-17-hydroxy-3-oxo gamma-lactone methyl ester; EPLERENONE 98%; EPLERENONE USP STANDARD; EplerenoneC24H3006 |
| 分子量 | 414.49 |
| 分子式 | C24H30O6 |
| EINECS编号 |
综合信息
查看供应
物理化学性质
熔点 241-243°C
依普利酮用途
依普利酮是一种新型选择性醛固酮受体拮抗剂，2002年被国家食品与药品管理局批准应用于临床，纯品为白色或类白色晶体，拮抗醛固酮作用较螺内酯强，且对雄激素和黄体酮受体的亲和力极低，不良反应小，对治疗高血压、心力衰竭和心肌梗死有确切疗效，不良反应较少，耐受性好，是螺内酯的良好替代药物。
对联用多种降压药未能控制的重度高血压，加用依普利酮可使血压明显降低，尤其收缩压下降更为显著。与血管紧张素转化酶抑制因子(ACEI)和β受体阻滞剂联用治疗对严重心力衰竭和心肌梗死可提高患者生活质量和降低死亡率。
强心药
应用领域
上下游产品信息
化学品安全说明书(MSDS)
储运特性
安全术语
风险术语
上游原料
3-Oxopregna-4,6-diene-21,17-carbolactone11-Alpha-hydroxy-3-oxo-17-alpha-pregna-4,6-diene-21,17-carbolactoneAcetone cyanohydrin; 2-Hydroxy-2-methylpropanenitrile; 2-Hydroxy-2-methylpropionitrile; 2-Hydroxyisobutyronitrile; 2-Methyllactonitrile; alpha-Hydroxyisobutyronitrile4'-Amino-5-beta-cyano-11-alpha-hydroxy-7-alpha,4-metheno-3-oxo-17-alpha-pregnane-21,17-carbolactone5-beta-Cyano-11-alpha-hydroxy-4,7-alpha-methano-3,4'-dioxo-17-alpha-pregnane-21,17-carbolactone7-Alpha-(methoxycarbonyl)-11-alpha-hydroxy-3-oxoproegn-4-ene-21,17-carbolatone7-Alpha-(methoxycarbonyl)-11-alpha-(methylsulfonyloxy)-3-oxopregn-4-ene-21,17-carbolactone7-Alpha-(methoxycarbonyl)-3-oxopregna-4,9(11)-diene-21,17-carbolactone3-Oxopregna-4,6-diene-21,17-carbolactoneAcetone cyanohydrin; 2-Hydroxy-2-methylpropanenitrile; 2-Hydroxy-2-methylpropionitrile; 2-Hydroxyisobutyronitrile; 2-Methyllactonitrile; alpha-Hydroxyisobutyronitrile7-Alpha-(methoxycarbonyl)-3-oxopregna-4,9(11)-diene-21,17-carbolactone4'-Amino-5-beta-cyano-7-alpha,4-metheno-3-oxo-17-alpha-pregnane-21,17-carbolactone5-beta-Cyano-4,7-alpha-methano-3,4'-dioxo-17-alpha-pregnane-21,17-carbolactone7-Alpha-(methoxycarbonyl)-3-oxopregn-4-ene-21,17-carbolactone7-Alpha-(methoxycarbonyl)-9-alpha-hydroxy-3-oxopregn-4-ene-21,17-carbolactone7-Alpha-(methoxycarbonyl)-11-beta-hydroxy-3-oxopregn-4-ene-21,17-carbolactone7-Alpha-(methoxycarbonyl)-3-oxopregna-4,9(11)-diene-21,17-carbolactone(8S,10R,13S,14S)-3-methoxy-10,13-dimethyl-1,2,7,8,10,12,13,14,15,16-decahydro-17H-cyclopenta[a]phenanthren-17-one3-Methoxyspiro[androsta-3,5,9(11)-triene-17(S),2'-oxirane]21-(Ethoxycarbonyl)-3-methoxypregan-3,5,9(11)-triene-21,17-carbolactone3-Methoxypregna-3,5,9(11)-triene-21,17-carbolactone3-Oxopregna-4,9(11)-diene-21,17-carbolactone3-Oxopregan-4,6,9(11)-triene-21,17-carbolactone4'-Amino-5-beta-cyano-7-alpha,4-metheno-3-oxo-17-alpha-pregn-9(11)-ene-21,17-carbolactone5-beta-Cyano-4,7-alpha-methano-3,4'-dioxo-17-alpha-pregn-9(11)-ene-21,17-carbolactone(8S,10R,13S,14S)-3-methoxy-10,13-dimethyl-1,2,7,8,10,12,13,14,15,16-decahydro-17H-cyclopenta[a]phenanthren-17-one3-Methoxyspiro[androsta-3,5,9(11)-triene-17(S),2'-oxirane]21-(Ethoxycarbonyl)-3-methoxypregan-3,5,9(11)-triene-21,17-carbolactone3-Methoxypregna-3,5,9(11)-triene-21,17-carbolactone3-Oxopregna-4,9(11)-diene-21,17-carbolactone9-alpha,11-alpha-Epoxy-3-oxopregn-4-ene-21,17-carbolactone9-alpha,11-alpha-Epoxy-3-oxopregna-4,6-diene-21,17-carbolactone4'-Amino-5-beta-cyano-9-alpha,11-alpha-epoxy-7-alpha,4-metheno-3-oxo-17-alpha-pregnane-21,17-carbolactone5-beta-Cyano-9-alpha,11-alpha-epoxy-4,7-alpha-methano-3,4'-dioxo-17-alpha-pregnane-21,17-carbolactone4-Androstene-3,7-dione; Androstenedione; (8R,9S,10R,13S)-10,13-Dimethyl-7,8,9,10,11,12,13,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-3,17(2H,6H)-dione11-Alpha-hydroxy-3-oxo-17-alpha-pregna-4,6-diene-21,17-carbolactone(8S,9S,10R,11R,13S,14S)-11-hydroxy-10,13-dimethyl-7,8,9,10,11,12,13,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-3,17(2H,6H)-dione(8S,9S,10R,11R,13S,14S)-3-ethoxy-11-hydroxy-10,13-dimethyl-1,2,7,8,9,10,11,12,13,14,15,16-dodecahydro-17H-cyclopenta[a]phenanthren-17-one3-Ethoxy-11-alpha-hydroxyspiro[androsta-3,5-diene-17(S),2'-oxirane]3-Ethoxy-21-(ethoxycarbonyl)-11-alpha-hydroxypregna-3,5-diene-21,17-carbolactone3-Ethoxy-11-alpha-hydroxypregna-3,5-diene-21,17-carbolactone3-Oxo-11-alpha-hydroxypregn-4-ene-21,17-carbolactone
